Predictive value of 99 mTc-labelled MAA scintigraphy for 90 Y-microspheres distribution in radioembolization treatment with resin microspheres in primary and secondary hepatic tumors

[1]  R. Dhanasekaran,et al.  Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study , 2017, American journal of clinical oncology.

[2]  A. Haug,et al.  Systematic Evaluation of Tumoral 99mTc-MAA Uptake Using SPECT and SPECT/CT in 502 Patients Before 90Y Radioembolization , 2015, The Journal of Nuclear Medicine.

[3]  N. Obuchowski,et al.  Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post-Radioembolization 90Y PET , 2014, Front. Oncol..

[4]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. Orsi,et al.  Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective , 2014, Front. Oncol..

[6]  A. Haug,et al.  Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors , 2013, Oncology.

[7]  T. W. Barber,et al.  Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y‐90 radiation synovectomy , 2013, Journal of medical imaging and radiation oncology.

[8]  Marnix G E H Lam,et al.  99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic Radioembolization , 2013, The Journal of Nuclear Medicine.

[9]  H. Amthauer,et al.  Predictive Value of Intratumoral 99mTc-Macroaggregated Albumin Uptake in Patients with Colorectal Liver Metastases Scheduled for Radioembolization with 90Y-Microspheres , 2013, The Journal of Nuclear Medicine.

[10]  C. Verslype,et al.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[12]  H. Biersack,et al.  Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization , 2011, The Journal of Nuclear Medicine.

[13]  F. Forrer,et al.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  A. Haug,et al.  18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  P. Flamen,et al.  Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres , 2008, Physics in medicine and biology.

[16]  M. Burton,et al.  Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. , 2001, Physics in medicine and biology.

[17]  M. Burton,et al.  Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. , 2000, Physics in medicine and biology.

[18]  A. Li,et al.  Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours , 1996, European Journal of Nuclear Medicine.